Cyclo Therapeutics Inc. (CYTH)
0.68
0.03 (4.62%)
At close: Jan 14, 2025, 3:28 PM
0.68
0.00%
After-hours Jan 14, 2025, 03:29 PM EST
undefined% (undefined)
| Bid | 0.67 |
| Market Cap | 19.46M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.9 |
| PE Ratio (ttm) | -0.76 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 0.71 |
| Volume | 40,116 |
| Avg. Volume (20D) | 35,547 |
| Open | 0.68 |
| Previous Close | 0.65 |
| Day's Range | 0.66 - 0.70 |
| 52-Week Range | 0.55 - 2.12 |
| Beta | undefined |
About CYTH
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, n...
Analyst Forecast
According to 3 analyst ratings, the average rating for CYTH stock is "Hold." The 12-month stock price forecast is $0.95, which is an increase of 39.71% from the latest price.
Buy 33.33%
Hold 66.67%
Sell 0.00%
Next Earnings Release
Cyclo Therapeutics Inc. is scheduled to release its earnings on Mar 17, 2025,
before market opens.
Analysts project revenue of $322.00K, reflecting a 3.40% YoY growth and earnings per share of -0.16, making a -30.43% decrease YoY.
Analysts project revenue of $322.00K, reflecting a 3.40% YoY growth and earnings per share of -0.16, making a -30.43% decrease YoY.
4 months ago ·
Source
-26.98%
Cyclo Therapeutics shares are trading lower after ...
Unlock content with
Pro Subscription
